Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 7 → 10 locations
  2. Study sites: 8 to 9
  3. Study sites: 7 to 8
  4. Study sites: 6 to 7
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 6 of 8 entries
  5. Study sites: 5 to 6v7
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 3 to 5v6
  2. Study sites: 2 to 3v5
  3. Study sites: 1 to 2v4
  4. Start date changed from estimate of Jun 12, 2026 to May 28, 2026v3
  1. Recruitment opened
    • Study sites: 0 to 1
    v2
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
556 trials monitored
See 33 trials at risk
Breast Cancer
5,466 trials monitored
See 312 trials at risk
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.
Trial Details
NCT Number NCT07604571
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Advanced HR+/HER2- Breast Cancer
Enrollment 194 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov